M.K.B. Parmar

1.5k total citations · 1 hit paper
24 papers, 757 citations indexed

About

M.K.B. Parmar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Reproductive Medicine. According to data from OpenAlex, M.K.B. Parmar has authored 24 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Reproductive Medicine. Recurrent topics in M.K.B. Parmar's work include Ovarian cancer diagnosis and treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (3 papers). M.K.B. Parmar is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (3 papers). M.K.B. Parmar collaborates with scholars based in United Kingdom, India and United States. M.K.B. Parmar's co-authors include Richard Stephens, Lesley Stewart, R L Souhami, Jean‐Pierre Pignon, Thierry Le Chevalier, R. Arriagada, Sarah Burdett, Julian P. T. Higgins, A. Aupérin and David H. Johnson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

M.K.B. Parmar

22 papers receiving 730 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

2010 444 citations R. Arriagada, A. Aupérin et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.K.B. Parmar United Kingdom	9	466	307	97	97	91	24	757
Eve T. Rodler United States	17	470 1.0×	592 1.9×	59 0.6×	62 0.6×	171 1.9×	29	920
Kazım Uygun Türkiye	15	215 0.5×	312 1.0×	26 0.3×	155 1.6×	112 1.2×	56	683
Benjamin Lyons United States	9	182 0.4×	468 1.5×	209 2.2×	39 0.4×	146 1.6×	9	868
Elena Lorenzi Italy	18	559 1.2×	234 0.8×	75 0.8×	43 0.4×	158 1.7×	43	1.0k
Renske Altena Sweden	11	103 0.2×	225 0.7×	111 1.1×	153 1.6×	85 0.9×	31	603
Ieta D’Costa Australia	12	148 0.3×	130 0.4×	82 0.8×	152 1.6×	80 0.9×	24	517
Serap Akyürek Türkiye	12	194 0.4×	135 0.4×	145 1.5×	110 1.1×	69 0.8×	50	623
Brent Shoji United States	8	226 0.5×	355 1.2×	31 0.3×	233 2.4×	172 1.9×	8	807
Che‐Kai Tsao United States	15	356 0.8×	260 0.8×	58 0.6×	253 2.6×	158 1.7×	80	769
H. Kucera Austria	17	146 0.3×	86 0.3×	65 0.7×	310 3.2×	57 0.6×	83	1.0k

Countries citing papers authored by M.K.B. Parmar

Since Specialization

Citations

This map shows the geographic impact of M.K.B. Parmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.K.B. Parmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.K.B. Parmar more than expected).

Fields of papers citing papers by M.K.B. Parmar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.K.B. Parmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.K.B. Parmar. The network helps show where M.K.B. Parmar may publish in the future.

Co-authorship network of co-authors of M.K.B. Parmar

This figure shows the co-authorship network connecting the top 25 collaborators of M.K.B. Parmar. A scholar is included among the top collaborators of M.K.B. Parmar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.K.B. Parmar. M.K.B. Parmar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parmar, M.K.B., et al.. (2023). Survey on Knowledge and Attitudes toward Hearing Loss and Assistive Listening Technology among Educational Professionals. SHILAP Revista de lepidopterología. 37(1). 21–26. 1 indexed citations

Sharma, Mukesh, et al.. (2023). Prospective of Professionals toward Role of Speech-language Pathologist in Assessment and Management of Dysphagia. SHILAP Revista de lepidopterología. 11(1). 28–30.

Akram, Ali, Fiona C. Ingleby, Alex Hoyle, et al.. (2019). Docetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden. Annals of Oncology. 30. v325–v326. 4 indexed citations

Embleton-Thirsk, Andrew, Timothy Perren, Alistair Cook, et al.. (2015). 2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC). European Journal of Cancer. 51. S546–S546. 1 indexed citations

Perren, Timothy, W. Schroeder, Éric Pujade-Lauraine, et al.. (2013). ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. UCL Discovery (University College London). 21 indexed citations

Pujade-Lauraine, Éric, Timothy Perren, Sven� Mahner, et al.. (2013). ICON7: FINAL OVERALL SURVIVAL RESULTS IN THE GCIG PHASE III RANDOMISED TRIAL OF BEVACIZUMAB IN NEWLY DIAGNOSED OVARIAN CANCER. UCL Discovery (University College London). 6 indexed citations

James, Nicholas D., Matthew R. Sydes, M. Mason, et al.. (2011). Celecoxib Plus Hormone Therapy Vs Hormone Therapy Alone for Hormone-sensitive Prostate Cancer: First Results From the STAMPEDE Randomised Controlled Trial (MRC PR08). European Journal of Cancer. 47. 11–11. 8 indexed citations

Arriagada, R., A. Aupérin, Sarah Burdett, et al.. (2010). Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. The Lancet. 375(9722). 1267–1277. 444 indexed citations breakdown →

Richman, Susan D., Lindsay C Thompson, Philip Quirke, et al.. (2009). 6125 Topoisomerase-1 (Topo1) as a predictive and prognostic factor in colorectal cancer chemotherapy. European Journal of Cancer Supplements. 7(2). 360–360.

10.

Braun, Michael, Susan D. Richman, Julian Adlard, et al.. (2006). Association of topoisomerase-1 (Topo1) with the efficacy of chemotherapy in a randomized trial for advanced colorectal cancer patients (FOCUS). Journal of Clinical Oncology. 24(18_suppl). 10009–10009. 4 indexed citations

11.

Quinn, Michael, E. Åvall‐Lundqvist, Andreas du Bois, et al.. (2005). History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004. Annals of Oncology. 16. viii5–viii6. 5 indexed citations

12.

Brown, Julia, H. Thorpe, Vicky Napp, et al.. (2005). Assessment of Quality of Life in the Supportive Care Setting of the Big Lung Trial in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 23(30). 7417–7427. 62 indexed citations

13.

Sandercock, Josie, M.K.B. Parmar, Valter Torri, & W. Qian. (2002). First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. British Journal of Cancer. 87(8). 815–824. 86 indexed citations

14.

Whelan, Peter, Gareth Griffiths, Michael J. Stower, et al.. (2001). Preliminary results of a MRC randomised controlled trial of post-operative irrigation of superficial bladder cancer. UCL Discovery (University College London). 11 indexed citations

15.

Colombo, N., J. Baptist Trimbos, David Guthrie, et al.. (2001). ACTION + ICON1: two parallel randomised phased III trials comparing adjuvant chemotherapy to no adjuvant chemotherapy following surgery in women with high risk early ovarian cancer. European Journal of Cancer. 37. S276–S276. 2 indexed citations

16.

Collette, Laurence, R. J. Sylvester, L. Denis, et al.. (1999). The three-month recurrence as a prognostic factor for the long term outcome in TaT1 bladder cancer. European Journal of Cancer. 35. S342–S342. 1 indexed citations

17.

Duffy, Austin G., et al.. (1997). 25 Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales. Lung Cancer. 18. 9–9. 3 indexed citations

18.

Souhami, R L, Lesley Stewart, R. Arriagada, et al.. (1994). A data-based meta-analysis of randomised trials of chemotherapy versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 11. 24–25. 9 indexed citations

19.

Stewart, Lesley, David Guthrie, M.K.B. Parmar, & Carmen J. Williams. (1992). Chemotherapy in advanced ovarian cancer.. BMJ. 304(6819). 119–119. 6 indexed citations

20.

Hall, R. & M.K.B. Parmar. (1990). Randomised intercontinental trial of locoregional therapy with or without neoadjuvant chemotherapy.. PubMed. 353. 105–9. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact